Thank key Clearside macular an is you, two John. Uveitic attractive for opportunity for edema reasons.
the these unmet high vision option of provide cause current their despite potential for nearly need of area with medical have patients a uveitis. leading the patients is new XIPERE for an receiving these is treatments edema to this XX% treatment patients. and effective as for uveitis of has loss persistent it First,
can these year, launch of patients by receive the approval. for we base the retina we preparation treated our we to to are and launch continue whom Second, uveitis and access believe concentrated in and XIPERE potential readily tremendous of prepared and we a make receive executing specialists will community next against we progress of should be healthcare strategy quarter effectively first educate efficiently the
we uveitis and the like that will expected provide in to able confident thus and a communities are I efficient and plans our prudent retina We discuss now manner. the the base progress far. and some research made of physician of highlight level to we've would by be service to
us for adopters the XIPERE. uveitis services In believe those order audience. understand Let's whom will start is and with be to particularly of truly the offer, retinal we it important earliest the the optimize will that know and specialist we physician to
We and services adoption them physicians continue create to best is we educational the materials feedback on and can This these serve their as programs required to how and direct the and patients. crucial their of gather we practice from current feedback and reimbursement managers our support product.
our on For one is top instance, suprachoroidal physicians priorities. injection these training of procedure a
options level a for developing hands-on including individual order provide physicians right needs. video to each sessions of demonstrations in are training prep support variety We materials, of and the
physician buy will in As purchase will practice administered XIPERE a the ensure and by bill discussed last the physicians from quarter, and therapeutic. then I both we're patient and this will insurers. and patients, means bill be access. their we this physician To who This oversee office drug reimbursement to input smoothly managers and solutions other the support therapies process services gathering currently evaluating goes offices process are for for practice be
have and our ensure and access XIPERE. also we're qualifies feedback input treatment will to gathering public any payers patient who private to from for Importantly,
approval. is continue would stakeholders Financial ensure patient. most keeping financial commercialization we we and call deploy you field Officer, over forward made staff services ensure this all the for and the the well-equipped extensive to results. prepared of support the I multiple our launch fronts Charlie physicians, review our I programs with All to and Deignan to discussed now engagement in to progress done We've and like our we across of FDA our updated we'll on XIPERE of their being to turn look force successful should Chief to are receive to efforts
